Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of Mylotarg that
can be combined with chemotherapy in patients receiving allogeneic bone marrow
transplantation. Researchers will study the effects of this treatment combination on patients
with high-risk acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome.
Primary Objective:
1. To determine the safety and maximum tolerated dose of Mylotarg as part of a
reduced-intensity preparative regimen patients undergoing related, mismatched-related or
matched unrelated donor transplantation.
Secondary Objectives:
1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with
this strategy.
2. To evaluate the incidence and severity of GVHD in this population
3. To evaluate disease-free and overall survival and relapse rates.